John A. Curran

3.8k total citations
15 papers, 486 citations indexed

About

John A. Curran is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, John A. Curran has authored 15 papers receiving a total of 486 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Molecular Biology, 6 papers in Pulmonary and Respiratory Medicine and 6 papers in Oncology. Recurrent topics in John A. Curran's work include Cancer Genomics and Diagnostics (4 papers), Lung Cancer Treatments and Mutations (4 papers) and Colorectal Cancer Treatments and Studies (3 papers). John A. Curran is often cited by papers focused on Cancer Genomics and Diagnostics (4 papers), Lung Cancer Treatments and Mutations (4 papers) and Colorectal Cancer Treatments and Studies (3 papers). John A. Curran collaborates with scholars based in United States. John A. Curran's co-authors include Isett Laux, Charles Tindell, Doron Lipson, David B. Agus, Roman Yelensky, Sean R. Downing, Vincent A. Miller, Jeffrey S. Ross, Jie He and Gary A. Palmer and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and Clinical Cancer Research.

In The Last Decade

John A. Curran

13 papers receiving 473 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
John A. Curran United States	6	265	169	135	133	96	15	486
John A. Stolk United States	5	344 1.3×	91 0.5×	182 1.3×	152 1.1×	42 0.4×	6	564
Meraj Aziz United States	12	353 1.3×	211 1.2×	82 0.6×	191 1.4×	64 0.7×	18	617
Imke Müller Germany	8	228 0.9×	183 1.1×	199 1.5×	329 2.5×	34 0.4×	8	494
Mary Stanley United States	7	176 0.7×	178 1.1×	54 0.4×	159 1.2×	43 0.4×	11	397
Marcell A. Szász Hungary	10	210 0.8×	148 0.9×	73 0.5×	128 1.0×	161 1.7×	16	534
Takeyasu Katada Japan	12	350 1.3×	133 0.8×	100 0.7×	193 1.5×	107 1.1×	22	511
Ceren Gönen Korkmaz Norway	10	226 0.9×	84 0.5×	142 1.1×	82 0.6×	38 0.4×	14	450
Shazia Irshad United Kingdom	9	209 0.8×	100 0.6×	124 0.9×	110 0.8×	28 0.3×	12	356
Denise Treue Germany	13	198 0.7×	147 0.9×	103 0.8×	154 1.2×	32 0.3×	18	399
Kaumudi Bhawe United States	7	317 1.2×	139 0.8×	216 1.6×	114 0.9×	66 0.7×	9	589

Countries citing papers authored by John A. Curran

Since Specialization

Citations

This map shows the geographic impact of John A. Curran's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John A. Curran with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John A. Curran more than expected).

Fields of papers citing papers by John A. Curran

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John A. Curran. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John A. Curran. The network helps show where John A. Curran may publish in the future.

Co-authorship network of co-authors of John A. Curran

This figure shows the co-authorship network connecting the top 25 collaborators of John A. Curran. A scholar is included among the top collaborators of John A. Curran based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John A. Curran. John A. Curran is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

Lozinsky, Yaroslav, Sergey Starikov, Felix Frenkel, et al.. (2021). Analytical and clinical validation of the BostonGene tumor portrait assay.. Journal of Clinical Oncology. 39(15_suppl). e15085–e15085.

Hawryluk, Matthew, Kai Wang, Juliann Chmielecki, et al.. (2014). Clinical application of comprehensive next-generation sequencing-based genomic profiling for identification of actionable genomic alterations in pediatric solid tumors and hematolymphoid malignancies: The Foundation Medicine pediatric experience.. Journal of Clinical Oncology. 32(15_suppl). 10035–10035. 2 indexed citations

Ross, Jeffrey S., Kai Wang, Rami N. Al‐Rohil, et al.. (2013). Advanced urothelial carcinoma: next-generation sequencing reveals diverse genomic alterations and targets of therapy. Modern Pathology. 27(2). 271–280. 119 indexed citations

Ross, Jeffrey S., Kai Wang, Christine E. Sheehan, et al.. (2013). Relapsed Classic E-Cadherin ( CDH1 )–Mutated Invasive Lobular Breast Cancer Shows a High Frequency of HER2 ( ERBB2 ) Gene Mutations. Clinical Cancer Research. 19(10). 2668–2676. 96 indexed citations

Miller, Vincent A., Jeffrey S. Ross, Kai Wang, et al.. (2013). Use of next-generation sequencing (NGS) to identify actionable genomic alterations (GA) in diverse solid tumor types: The Foundation Medicine (FMI) experience with 2,200+ clinical samples.. Journal of Clinical Oncology. 31(15_suppl). 11020–11020. 5 indexed citations

Palmer, Gary A., Vincent A. Miller, John A. Curran, et al.. (2012). Next-generation sequencing (NGS) to identify actionable genomic changes in common and rare solid tumors: The FMI experience with the initial 50 consecutive patients.. Journal of Clinical Oncology. 30(15_suppl). 10590–10590. 2 indexed citations

Ross, Jeffrey S., Doron Lipson, Roman Yelensky, et al.. (2011). Comprehensive next-generation sequencing for clinically actionable mutations from formalin-fixed cancer tissues.. Journal of Clinical Oncology. 29(15_suppl). 10564–10564. 5 indexed citations

Gross, Mitchell E., Isett Laux, Jonathan E. Katz, et al.. (2007). β-2-Microglobulin Is an Androgen-Regulated Secreted Protein Elevated in Serum of Patients with Advanced Prostate Cancer. Clinical Cancer Research. 13(7). 1979–1986. 51 indexed citations

Jain, Anjali, Charles Tindell, Isett Laux, et al.. (2005). Epithelial membrane protein-1 is a biomarker of gefitinib resistance. Proceedings of the National Academy of Sciences. 102(33). 11858–11863. 74 indexed citations

10.

Curran, John A.. (2003). Topical Chemical Carcinogen Treatment in Mice. Humana Press eBooks. 174. 391–399. 1 indexed citations

11.

Player, Audrey, John W. Gillespie, Takeshi Fujii, et al.. (2003). Identification of TDE2 gene and its expression in non‐small cell lung cancer. International Journal of Cancer. 107(2). 238–243. 24 indexed citations

12.

Curran, John A.. (2003). In Vivo Assay of Cellular Proliferation. Humana Press eBooks. 174. 379–389. 4 indexed citations

13.

Nacht, Mariana, Tatiana Dracheva, Yuhong Gao, et al.. (2001). Molecular characteristics of non-small cell lung cancer. Proceedings of the National Academy of Sciences. 98(26). 15203–15208. 99 indexed citations

14.

Curran, John A., et al.. (1970). A controlled study of the effects of gamfexine in phenothiazine-treated patients.. PubMed. 12(4). 230–3. 2 indexed citations

15.

Ettinger, Max & John A. Curran. (1970). Liver disease and phenothiazines. Involuntary movements.. PubMed. 53(7). 731–6. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact